Tag: MSD

FDA to Review Six sBLAs for KEYTRUDA

Merck, known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review six supplemental Biologics License Applications (sBLA...

IBM, KPMG, MSD, and Walmart Take Part in FDA Pilot Program

IBM, KPMG, Merck, and Walmart announced that the companies have been selected by the United States Food and Drug Administration (FDA) to be included in a program in support of the U.S. Drug Supply Cha...

AstraZeneca and MSD’s Lynparza Doubled Progression-Free Survival in Pancreatic Cancer

AstraZeneca and MSD Inc., Kenilworth, N.J., US (MSD: known as Merck & Co., Inc. inside the US and Canada) announced detailed results from the Phase III POLO trial at the 2019 American Societ...

Local Indian Pharma Companies to Challenge MNCs in Pneumonia Vaccine

The duopoly of pneumonia vaccines in India is in for some shake-up soon, as homegrown players like Aurobindo Pharma, Cadila Healthcare (Zydus Cadila), and Serum Institute are readying their vaccin...

ThiIrd Lynparza Indication in EU

AstraZeneca and MSD Inc., Kenilworth, N.J., US (MSD: known as Merck & Co., Inc. inside the US and Canada) today announced the European Commission has approved Lynparza (olaparib) as a monotherapy ...

BTD for AstraZeneca and Merck Med

AstraZeneca and MSD, Inc., Kenilworth, NJ, US announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for the MEK 1/2 inhibitor and potential new me...

MSD and Instituto Butantan to collaborate on dengue vaccine

MSD and Instituto Butantan, a non-profit producer of immunobiologic products announced a collaboration agreement to develop vaccines against dengue virus disease, the mosquito-borne infection.

MSD receives EU approval for two HIV medicines

MSD (known as Merck in the USA and Canada) announced that the European Commission has approved DELSTRIGO and PIFELTRO for the treatment of HIV-1 infection.

Sutro Biopharma entered into collaboration with MSD

Sutro Biopharma has signed a collaboration and licensing agreement with MSD (known as Merck in USA and Canada), to discover and develop novel immune-modulating therapies for cancer and autoimmune disorders.

WHO employs experimental Ebola vaccine for the ongoing outbreak in Congo

In response to the ongoing outbreak of Ebola in Democratic Republic of the Congo, WHO with The Government of the Democratic Republic of Congo preparing to vaccinate high risk populations against Ebola virus disease.

MSD and Moderna Therapeutics will develop novel cancer vaccines

Merck, known as MSD outside the United States and Canada, and Moderna Therapeutics announced a strategic collaboration and license agreement to develop and commercialize novel messenger RNA-based personalized cancer vaccines.

MSD start clinical studies of its investigational polyvalent conjugate vaccine

MSD (known as "Merck" in USA and Canada) announced that the company is beginning two Phase 3 studies of PCV-15 (V114), its investigational polyvalent conjugate vaccine for the prevention of pneumococcal disease.

Immutep starts a clinical trial collaboration with MSD

Immutep, a leading Australian biotechnology company, announced that it has entered into a clinical trial collaboration and supply agreement with MSD to evaluate the combination of Immutep’s lead immunotherapy product

Samsung Bioepis biosimilar cancer drug begun to sell in Europe

Korean biopharmaceutical firm Samsung Bioepis informed that its biosimilar cancer drug Ontruzant has begun selling in Britain following approval from a European regulator (EMA).

Eisai and MSD will jointly develop and commercialize a thyroid cancer therapy

Eisai Co., Ltd. and MSD agreed upon a strategic collaboration for the worldwide co-development and co-commercialization of LENVIMA (lenvatinib mesylate), an orally available tyrosine kinase inhibitor discovered by Eisai.

MSD and AKRIKHIN localized manufacturing of sitagliptin in Russia

MSD, an innovative global pharmaceutical company, and AKRIKHIN, a leading Russian pharmaceutical manufacturer, announced the successful localization of 100 mg finished dosage form of sitagliptin.